IVACAFTOR TREATMENT IN FOUR PATIENTS WITH SEVERE LUNG DISEASE AND 2789+5G-> A CFTR MUTATION

Botti M.; Terlizzi V; Cavicchi M.; Neri A.; Taccetti G.

首页> 外文期刊>Pediatric Pulmonology >IVACAFTOR TREATMENT IN FOUR PATIENTS WITH SEVERE LUNG DISEASE AND 2789+5G-> A CFTR MUTATION

【24h】

IVACAFTOR TREATMENT IN FOUR PATIENTS WITH SEVERE LUNG DISEASE AND 2789+5G-> A CFTR MUTATION

机译：Ivacafeaferor治疗4例严重肺病患者和2789 + 5g-> CFTR突变

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pediatric Pulmonology》 |2019年第2期|共1页
作者
Botti M.; Terlizzi V; Cavicchi M.; Neri A.; Taccetti G.;
展开▼
作者单位

Univ Pisa Santa Chiara Hosp Dept Pediat Pisa Italy;

Meyer Childrens Hosp Cyst Fibrosis Ctr Dept Pediat Florence Italy;

Meyer Childrens Hosp Cyst Fibrosis Ctr Dept Pediat Florence Italy;

Meyer Childrens Hosp Cyst Fibrosis Ctr Dept Pediat Florence Italy;

Meyer Childrens Hosp Cyst Fibrosis Ctr Dept Pediat Florence Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词
入库时间 2022-08-20 06:04:28

相似文献

外文文献
中文文献
专利

1. IVACAFTOR TREATMENT IN FOUR PATIENTS WITH SEVERE LUNG DISEASE AND 2789+5G-> A CFTR MUTATION [J] . Botti M., Terlizzi V, Cavicchi M., Pediatric Pulmonology . 2019,第Suppla2期

机译：Ivacafeaferor治疗4例严重肺病患者和2789 + 5g-> CFTR突变
2. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial [J] . BoyleM.P., BellS.C., KonstanM.W., The lancet. Respiratory medicine. . 2014,第7期

机译：CFTR校正剂（lumacaftor）和CFTR增强剂（ivacaftor）用于治疗phe508del CFTR突变的囊性纤维化患者：2期随机对照试验
3. Case History: Kalydeco (R) (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CFTR Mutation [J] . Hadida Sabine, Van Goor Frederick, Dinehart Kirk, Annual reports in medicinal chemistry. . 2014,第Null期

机译：病历：Kalydeco（R）（VX-770，Ivacaftor），一种CFTR增强剂，用于治疗囊性纤维化和G551D-CFTR突变的患者
4. New Anti-Microbial Treatment of Purulent-Inflammatory Lung Diseases in Patients Supported by Long-Term Artificial Ventilation of Lungs [C] . EG. Nazirov, R.A. Ibadov, Z.A. Shanieva, NATO Advanced Study Institute on Biodefence: Advanced materials and methods for health protection . 2011

机译：长期人工通风肺部支撑患者的新型抗微生物治疗肺部
5. The investigation of quality of life, perceived disease severity, and adherence in patients with the G551D mutation receiving Ivacaftor therapy [D] . Hathorne, Heather 2015

机译：接受IVACafacor治疗的G551D突变患者的生活质量，感知疾病严重程度和依从性的调查
6. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized controlled trial [O] . Alexandra Quittner, Ellison Suthoff, Regina Rendas-Baum, 2015

机译：依伐卡托治疗对囊性纤维化和G551D-CFTR突变患者的影响：STRIVE随机对照试验中患者报告的结果
7. WS3.2 The effect of ivacaftor treatment on lung ventilation defects, as measured by hyperpolarized helium-3 MRI, on patients with cystic fibrosis and a G551D-CFTR mutation [O] . Altes T., Johnson M., Higgins M., 2014

机译：WS3.2依伐卡托治疗对囊性纤维化和G551D-CFTR突变的超极化氦3 MRI测量的肺通气缺陷的影响
8. Methods for Modulating PPAR Biological Activity for the Treatment of Diseases Caused By Mutations in the CFTR Gene. [R] . Freedman, S. D. 2005

机译：调节ppaR生物活性的方法用于治疗由CFTR基因突变引起的疾病。

IVACAFTOR TREATMENT IN FOUR PATIENTS WITH SEVERE LUNG DISEASE AND 2789+5G-> A CFTR MUTATION

著录项

相似文献

相关主题

期刊订阅